Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Lisa A. Raedler, PhD, RPh, Medical Writer

Medical Writer

Authored Items
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals, Melanoma
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals, Lymphoma
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals, Lymphoma
Infugem (Gemcitabine) First Formulation of Premixed, Ready-to-Administer Intravenous Chemotherapy Approved for Several Tumor Types
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals, Leukemia
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in Breast Cancer, FDA Approvals
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals, Leukemia
Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals
Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Approvals, Leukemia
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Lung Cancer
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Lymphoma
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Lymphoma
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Bladder Cancer
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Breast Cancer
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Multiple Myeloma
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Bladder Cancer
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Leukemia
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, Ovarian Cancer
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
TOP - November 2017, Vol 10, No 4 in Drug Updates
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles
Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles
Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)
Lisa A. Raedler, PhD, RPh, Medical Writer
Patient Assistance Profiler December 2016
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Online First in Drug Updates
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
TOP - August 2016, Vol 9, No 3 in Drug Updates
Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh, Medical Writer
TOP - February 2016, Vol 9, No 1 in Drug Updates
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
TOP November 2015 Vol 8 No 4 in Drug Updates
The Dynamic Partnership of Music and Medicine
Lisa A. Raedler, PhD, RPh, Medical Writer
TON - March/April 2014 Vol 7 No 2 in Supportive Care
Cancer Program Standards: Navigation and Survivorship: What’s Happening in the Field?
Lisa A. Raedler, PhD, RPh, Medical Writer
TON - January/February 2014 Vol 7 No 1 in Conference Correspondent
Highlights from Key Meetings in Hematology and Oncology
Brian Dinh, PharmD, Lisa A. Raedler, PhD, RPh, Medical Writer
TOP-Resident Reporter-September 2013
Highlights from Key Meetings in Hematology and Oncology
Brian Dinh, PharmD, Lisa A. Raedler, PhD, RPh, Medical Writer
Resident Reporter-September 2013
Last modified: May 4, 2017